Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
SAB Biotherapeutics Inc (SABS)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$3.18+1.92%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for SABS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Cash from operations stabilizes near negative $14.27 million by 2026-Q1 | A supporting condition in SAB Biotherapeutics Inc's published investment case. The stated target is >= -14.27 USD_MILLIONS. | Broken | Cash from operations worsens beyond negative $14.27 million by 2026-Q1 | Cash from operations: $-24.112M FY2026-Q2; GAAP. Published target: >= -14.27 USD_MILLIONS. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 6, 2026-24,112,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative clinical-stage growth, not an established earnings compounder. The multi-year thesis is in a watch state: management is advancing studies and manufacturing plans, but recent financial performance is weak and the risk label is high.
The valuation model shows a premium versus peers, while its expectations gap is elevated and the market setup is tagged as unjustified. In plain terms, expectations appear difficult to support given ongoing losses, no current revenue, and clinical uncertainty; confidence in this assessment is medium.
Near term, operating losses are likely to continue as the company funds clinical development, with no revenue impact yet from its manufacturing partnership. Enrollment completion for the Phase 2b SAFEGUARD study is expected by Q4 2026, with topline data anticipated in the second half of 2027. Near-term execution risk is elevated, including a stated risk of another earnings miss, and litigation filings are a recent negative development.
The multi-year thesis hinges on completing the SAB-142 studies and producing useful clinical results, alongside making progress toward manufacturing readiness. A guidance cut or further weakening in employment could add pressure to the business outlook, while stronger results and guidance from healthcare sector bellwethers could support sector momentum. The evidence does not establish how these factors will resolve.
Over the next one to three years, SABS is a high-risk clinical development story with meaningful execution milestones but weak current financial performance and no revenue. Its long-term thesis depends on clinical progress and evidence that development and manufacturing plans can advance. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Operating losses improve or stabilize near negative $20 million by 2026-Q1 | If operating losses and cash burn improve, the company could stabilize. | Under Pressure | Operating losses worsen beyond negative $20 million by 2026-Q1 | Operating income: $-23.377M FY2026-Q2; GAAP. Published target: >= -20.0 USD_MILLIONS. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 6, 2026-23,377,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue reaches at least $175 million by mid-2028 | The company targets about $175 million in revenue by mid-2028. | Intact | Revenue falls below $175 million by mid-2028 | Revenue: $0 FY2026-Q2; GAAP. Published target: >=175 USD_MILLIONS. Target period ends 2028-06-30; this observation covers 2026-Q2. Aug 6, 20260 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.98 → $-0.80 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.98 | $62,500 | 4 / 8 |
| 2026-07-25 | $-0.98 | $62,500 | 4 / 8 |
| 2026-07-26 | $-0.98 | $62,500 | 4 / 8 |
| 2026-07-27 | $-0.98 | $62,500 | 4 / 8 |
| 2026-07-28 | $-0.98 | $62,500 | 4 / 8 |
| 2026-07-29 | $-0.72 | $50,000 | 5 / 5 |
| 2026-07-30 | $-0.72 | $50,000 | 5 / 5 |
| 2026-07-31 | $-0.98 | $62,500 | 4 / 8 |
| 2026-08-01 | $-0.72 | $50,000 | 5 / 5 |
| 2026-08-02 | $-0.98 | $62,500 | 4 / 8 |
| 2026-08-03 | $-0.72 | $50,000 | 5 / 5 |
| 2026-08-04 | $-0.72 | $50,000 | 5 / 5 |
| 2026-08-05 | $-0.98 | $62,500 | 4 / 8 |
| 2026-08-06 | $-0.98 | $62,500 | 4 / 8 |
| 2026-08-08 | $-0.96 | $62,500 | 4 / 8 |
| 2026-08-09 | $-0.97 | $62,500 | 4 / 8 |
| 2026-08-10 | $-0.97 | $62,500 | 4 / 8 |
| 2026-08-12 | $-0.72 | $50,000 | 5 / 5 |
| 2026-08-13 | $-0.95 | $71,430 | 5 / 7 |
| 2026-08-14 | $-0.72 | $50,000 | 5 / 5 |
| 2026-08-15 | $-0.72 | $50,000 | 5 / 5 |
| 2026-08-16 | $-0.72 | $50,000 | 6 / 5 |
| 2026-08-17 | $-0.72 | $50,000 | 6 / 5 |
| 2026-08-18 | $-0.72 | $50,000 | 6 / 5 |
| 2026-08-19 | $-0.72 | $50,000 | 6 / 5 |
| 2026-08-20 | $-0.83 | $50,000 | 6 / 5 |
| 2026-08-21 | $-0.83 | $50,000 | 6 / 5 |
| 2026-08-22 | $-0.83 | $50,000 | 6 / 5 |
| 2026-08-23 | $-0.83 | $50,000 | 6 / 5 |
| 2026-08-24 | $-0.80 | $50,000 | 6 / 5 |
| 2026-08-25 | $-0.80 | $50,000 | 6 / 5 |
| 2026-08-26 | $-0.80 | $50,000 | 6 / 5 |
| 2026-08-27 | $-0.80 | $50,000 | 6 / 5 |
| 2026-08-28 | $-0.80 | $50,000 | 6 / 5 |
| 2026-08-29 | $-0.80 | $50,000 | 6 / 5 |
| 2026-08-30 | $-0.80 | $50,000 | 6 / 5 |
| 2026-08-31 | $-0.80 | $50,000 | 6 / 5 |
| 2026-09-01 | $-0.80 | $50,000 | 6 / 5 |
| 2026-09-02 | $-0.80 | $50,000 | 6 / 5 |
| 2026-09-03 | $-0.80 | $50,000 | 6 / 5 |
| 2026-09-04 | $-0.80 | $50,000 | 6 / 5 |
| 2026-09-05 | $-0.80 | $50,000 | 6 / 5 |
| 2026-09-06 | $-0.80 | $50,000 | 6 / 5 |
| 2026-09-07 | $-0.80 | $50,000 | 6 / 5 |
| 2026-09-08 | $-0.80 | $50,000 | 6 / 5 |
| 2026-09-09 | $-0.80 | $50,000 | 6 / 5 |
| 2026-09-10 | $-0.80 | $50,000 | 6 / 5 |
| 2026-09-11 | $-0.80 | $50,000 | 6 / 5 |
| 2026-09-12 | $-0.80 | $50,000 | 6 / 5 |
| 2026-09-13 | $-0.80 | $50,000 | 6 / 5 |
| 2026-09-14 | $-0.80 | $50,000 | 6 / 5 |
| 2026-09-15 | $-0.80 | $50,000 | 6 / 5 |
| 2026-09-16 | $-0.80 | $50,000 | 6 / 5 |
| 2026-09-17 | $-0.80 | $50,000 | 6 / 5 |
| 2026-09-18 | $-0.80 | $50,000 | 6 / 5 |
| 2026-09-19 | $-0.80 | $50,000 | 6 / 5 |
| 2026-09-20 | $-0.80 | $50,000 | 6 / 5 |
| 2026-09-21 | $-0.80 | $50,000 | 6 / 5 |
| 2026-09-22 | $-0.80 | $50,000 | 6 / 5 |
| 2026-09-23 | $-0.80 | $50,000 | 6 / 5 |
| 2026-09-24 | $-0.80 | $50,000 | 6 / 5 |
| 2026-09-25 | $-0.80 | $50,000 | 6 / 5 |
| 2026-09-26 | $-0.80 | $50,000 | 6 / 5 |
| 2026-09-27 | $-0.80 | $50,000 | 6 / 5 |
| 2026-09-28 | $-0.80 | $50,000 | 6 / 5 |
| 2026-09-29 | $-0.80 | $50,000 | 6 / 5 |
| 2026-09-30 | $-0.80 | $50,000 | 6 / 5 |
| 2026-10-01 | $-0.80 | $50,000 | 6 / 5 |
| 2026-10-02 | $-0.80 | $50,000 | 6 / 5 |
| 2026-10-03 | $-0.80 | $50,000 | 6 / 5 |
| 2026-10-04 | $-0.80 | $50,000 | 6 / 5 |
| 2026-10-05 | $-0.80 | $50,000 | 6 / 5 |
| 2026-10-06 | $-0.80 | $50,000 | 6 / 5 |
| 2026-10-07 | $-0.80 | $50,000 | 6 / 5 |
| 2026-10-08 | $-0.80 | $50,000 | 6 / 5 |
| 2026-10-09 | $-0.80 | $50,000 | 6 / 5 |
| 2026-10-10 | $-0.80 | $50,000 | 6 / 5 |
| 2026-10-11 | $-0.80 | $50,000 | 6 / 5 |
| 2026-10-12 | $-0.80 | $50,000 | 6 / 5 |
| 2026-10-13 | $-0.80 | $50,000 | 6 / 5 |
| 2026-10-14 | $-0.80 | $50,000 | 6 / 5 |
| 2026-10-15 | $-0.80 | $50,000 | 6 / 5 |
| 2026-10-16 | $-0.80 | $50,000 | 6 / 5 |
| 2026-10-17 | $-0.80 | $50,000 | 6 / 5 |
| 2026-10-18 | $-0.80 | $50,000 | 6 / 5 |
| 2026-10-19 | $-0.80 | $50,000 | 6 / 5 |
| 2026-10-20 | $-0.80 | $50,000 | 6 / 5 |
| 2026-10-21 | $-0.80 | $50,000 | 6 / 5 |
| 2026-10-22 | $-0.80 | $50,000 | 6 / 5 |
| 2026-10-23 | $-0.80 | $50,000 | 6 / 5 |
| 2026-10-24 | $-0.80 | $50,000 | 6 / 5 |
| 2026-10-25 | $-0.80 | $50,000 | 6 / 5 |
| 2026-10-26 | $-0.80 | $50,000 | 6 / 5 |
| 2026-10-27 | $-0.80 | $50,000 | 6 / 5 |
| 2026-10-28 | $-0.80 | $50,000 | 6 / 5 |
| 2026-10-29 | $-0.80 | $50,000 | 6 / 5 |
| 2026-10-30 | $-0.80 | $50,000 | 6 / 5 |
| 2026-10-31 | $-0.80 | $50,000 | 6 / 5 |
| 2026-11-01 | $-0.80 | $50,000 | 6 / 5 |
| 2026-11-02 | $-0.80 | $50,000 | 6 / 5 |
| 2026-11-03 | $-0.80 | $50,000 | 6 / 5 |
| 2026-11-04 | $-0.80 | $50,000 | 6 / 5 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 11 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.